Skip to main navigation
X4 Pharmaceuticals
  • About
  • our medicine
  • science & pipeline
  • Patients
  • healthcare professionals
  • Investors
    • Company Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Governance
    • SEC Filings
    • Investor FAQs
  • Careers
X4 Pharmaceuticals X4 Pharmaceuticals
  • About
  • our medicine
  • science & pipeline
  • Patients
  • healthcare professionals
  • Investors
    • Company Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Governance
    • SEC Filings
    • Investor FAQs
  • Careers

News Releases

March 17, 2026
PDF Version
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 4, 2026
PDF Version
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
March 2, 2026
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2026
PDF Version
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
February 3, 2026
PDF Version
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
February 2, 2026
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

quick links

Quick Links

  • About
  • Patients
  • Investors
  • Careers
footer logo

contact

X4 Pharmaceuticals
61 North Beacon Street
4th Floor
Boston, MA 02134 Phone: 857.529.8300
© 2026 X4 Pharmaceuticals, Inc. All rights reserved.  

Live - Footer

Terms of Use | Privacy | Compliance and Ethics